<p>Intramedullary spinal cord metastasis in malignancies: an institutional analysis and review</p>

• DOI: 10.2147/ott.s193235
• Publication Date: 2019-06-20T19:56:36Z
• Authors: Jincai Lv; Bailong Liu; Xiaoyue Quan; Cheng Li; Lihua Dong; Min Liu
• Keywords: 03 medical and health sciences; 0302 clinical medicine; OncoTargets and Therapy; Original Research; 3. Good health

Background: Intramedullary spinal cord metastases (ISCM) in malignancies is a devastating issue with limited research. This study aims to identify the clinical features, management, prognostic factors, and outcomes of this special entity. Methods: A retrospective review 61 patients ISCM diagnosed treated our institute from June 2010 March 2018 was conducted (lost follow-up: 3). Data were retrieved according items including age, gender, primary tumor, interval occurrence, segments, other synchronous metastases. The interventions, response, systematically analyzed. Results: Lung cancer (67.21%) commonest source, followed by breast (14.75%). In total, 9.84% presented initially. mean span primaries 18.77 months (range=0-10 years). thoracic segment most commonly involved (77.05%), cervical (39.34%), lumbar level (34.43%), conus medullaris (6.56%). management challenging, since 55.74% individuals had poor physical condition (PS=3-4) 72.41% widespread dissemination synchronously (≥2 organs). Radiotherapy (RT) attained an objective response rate (ORR) 61.90% or 62.50% local control (LCR) 90.48% 87.50% for symptoms used alone strategies, respectively. bears dismal prognosis, median overall survival (OS) 4 months. Patients only one apparently better prognosis than those 2-4 segments (median OS=7.0 vs 3.0 months) (P<0.01). OS remarkably superior without any intervention OS=5.0 2.0 Conclusion: distinct entity needing more attention high incidence, prolonged survival, lack RT mainstay satisfactory effect. Multiple involvement no treatment are factors OS.